Protein Kinase Inhibitors: all 15,147 studies that test it

Page 127 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• Controlled Level EVERolimus in Acute Coronary SyndromesCompletedNCT01529554Phase 1/2
• Study of Axitinib and Temsirolimus in Solid TumorsCompletedNCT01529138Phase 1
• Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT01528085Phase 2
• Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and NeckStatus unknownNCT01527877Phase 2
• A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast CancerCompletedNCT01526369Phase 3
• Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With MetforminCompletedNCT01525823Phase 1
• Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced CholangiocarcinomaStatus unknownNCT01525719Phase 2
• A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1
• CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 2
• Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01524848Phase 2
• Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALLCompletedNCT01523977Phase 1
• PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor MalignanciesStatus unknownNCT01522989Phase 1
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedNCT01522820Phase 1
• First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
• Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedNCT01520220Phase 1
• Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT01518621Phase 2
• Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid TumorsCompletedNCT01518413Phase 1
• Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedNCT01517399Phase 1
• Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationCompletedNCT01516983Phase 1/2
• Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01515969Phase 1
• Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01515137Phase 1
• Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung CancerCompletedNCT01514877Phase 2
• Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaCompletedNCT01514526Phase 2
• Gastric Cancer RAD001 StudyCompletedNCT01514110Phase 1/2
• Pharmacodynamic Study of BKM120 in Breast CancerCompletedNCT01513356Early Phase 1
• Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaCompletedNCT01513187Phase 1/2
• Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 3
• First Line Gefitinib by FDG-PET Metabolic ResponseStatus unknownNCT01510990Phase 2
• Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary CirrhosisCompletedNCT01510860Phase 4
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
• PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation BloodCompletedNCT01509560Phase 2
• Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsTerminatedNCT01508104Phase 1
• Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular CarcinomaCompletedNCT01507064Phase 2
• A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT01506934Phase 1
• Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibCompletedNCT01506336Phase 2
• Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
• Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic CancerCompletedNCT01505413Phase 2
• Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male VolunteersCompletedNCT01504984Phase 1
• A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaStatus unknownNCT01503502Phase 2
• FLO +/- Pazopanib as First-line Treatment in Advanced Gastric CancerCompletedNCT01503372Phase 2
• Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never SmokersStatus unknownNCT01502202Phase 2
• BKM120 in Cancers With PIK3CA Activating MutationsWithdrawnNCT01501604Phase 2
• A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung CancerWithdrawnNCT01500824Phase 2
• Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)Active, not recruitingNCT01499888Phase 1/2
• Study of Efficacy and Safety of Sunitinib Given on an Individualized ScheduleCompletedNCT01499121Phase 2
• A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy VolunteersCompletedNCT01499004Phase 1
• Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue SarcomaCompletedNCT01498835Phase 1
• Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedNCT01498562Phase 2
• Dose-Escalation and Safety Trial of YN968D1CompletedNCT01497704Phase 1/2
• Lapatinib and Bortezomib in Patients With Advanced MalignanciesTerminatedNCT01497626Phase 1
• Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT01497444Phase 1
• Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary CancersCompletedNCT01497392Phase 1
• The Myocet/Lapatinib Study. ICORG 10-03, V5TerminatedNCT01495884Phase 1/2
• Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerTerminatedNCT01495247Phase 1/2
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsCompletedNCT01493869Phase 1
• Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung CancerCompletedNCT01493843Phase 2
• Kidney Allograft Dysfunction Without Reversible CausesWithdrawnNCT01492894Phase 4
• Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
• Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal CancerCompletedNCT01490749Phase 1
• Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) PatientsCompletedNCT01490476Phase 2
• Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) PatientsTerminatedNCT01489722Phase 1
• Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT01489566Phase 3
• Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell TransplantsTerminatedNCT01488253Phase 2
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female SubjectsCompletedNCT01487239Phase 1
• KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedNCT01487174Phase 3
• Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal CancerCompletedNCT01486251Not applicable
• A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KCompletedNCT01486017Phase 1
• A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.CompletedNCT01485926Phase 2
• Doxorubicin + BIBF 1120 in Patients for Ovarian CancerTerminatedNCT01485874Phase 1
• Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapyCompletedNCT01485809Phase 2
• Dose Escalation Study of Pazopanib Plus TH-302CompletedNCT01485042Phase 1
• A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New FormulationCompletedNCT01484964Phase 1
• A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01484847Not applicable
• Axitinib as Maintenance Treatment in Patients With Metastatic CRCTerminatedNCT01483638Phase 2
• Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01483014Phase 2
• Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial CancerCompletedNCT01482728Early Phase 1
• SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular CarcinomaCompletedNCT01482442Phase 3
• A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginCompletedNCT01482377Phase 1
• RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 ExpressionCompletedNCT01482299Phase 2
• Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT01480141Phase 2
• Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
• Protocol in Acute Myeloid Leukemia With FLT3-ITDCompletedNCT01477606Phase 2
• Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast CancerTerminatedNCT01477060Phase 2
• A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic MalignanciesTerminatedNCT01476657Phase 1
• A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male SubjectsCompletedNCT01474668Phase 1
• AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedNCT01474135Phase 2
• A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01473901Phase 1
• Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980CompletedNCT01473316Phase 1
• Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedNCT01473095Phase 1
• Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerTerminatedNCT01471964Phase 1/2
• Phase I Dose Escalating Study of TKI258CompletedNCT01471548Phase 1
• Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR MutationsStatus unknownNCT01470716Phase 2
• A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesCompletedNCT01470209Phase 1
• A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaTerminatedNCT01470131Phase 3
• Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft RecipientsCompletedNCT01469884Phase 4
• Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic MetastasesCompletedNCT01469572Phase 1
• A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid TumorsCompletedNCT01469130Phase 1

← Protein Kinase Inhibitors overview